47 results about "Barr virus" patented technology

A kit for detecting expression of AIRE and Treg in lymphatic tissue infected by EB virus comprises colloidal quantum well antibody conjugates, including a colloidal quantum well and protein AIRE and GITR conjugates and a colloidal quantum well and antibody CD25 and Foxp3 conjugates. The detection method comprises the following steps: (1) carrying out slicing treatment on a lymphatic tissue, and carrying out antigen repair by using an antigen repair liquid; (2) respectively adding colloidal quantum well proteins or antibodies coupled with different targets to dye the sections; (3) carrying out nucleus staining; and (4) collecting multi-channel fluorescence image information of the tissue slice, and judging expression levels and mutual relations of AIRE, Treg cells and dendritic cells in immune tolerance in combination with spatial positioning and intensity distribution of fluorescence signals of different channels. According to the invention, qualitative or quantitative multi-parameter and high-precision detection of the immune tolerance related cells in the lymph tissue is realized.

Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

To provide novel agents for the treatment or prevention of Epstein-Barr virus hepatitis. [Solution] A pharmaceutical composition for the treatment or prevention of Epstein-Barr virus hepatitis in a subject, comprising ibudilast, dipyridamole, or both as active ingredients.

The present invention relates to means and methods to prevent and / or treat Epstein-Barr virus (EBV) and EBV-induced diseases, such as EBV infection, infectious mononucleosis (IM), malignant or non-malignant post-transplant lymphoproliferative disorder (PTLD) and other EBV-associated diseases. In particular, the invention provides a SQAPLPCVL peptide that can be used in a treatment or a method of treatment to induce an EBV-specific immune response in a subject. The SQAPLPCVL can be used in a treatment or method of treatment as a vaccine against EBV and EBV-induced diseases. It is preferred herein that Epstein-Barr virus (EBV) and / or EBV-induced diseases are prevented.

This disclosure concerns methods of analysing and sequencing viral genomic DNA, in particular Epstein-Barr virus (EBV) genomic DNA, using viral-specific nucleic acid capture probes and long read sequencing.

The present application belongs to the field of medicine, and particularly relates to an EBNA1 inhibitor. The small molecule inhibitor recorded in the present application is proved by surface plasmon resonance (SPR) analysis to interact with EBNA1 in vitro and have high affinity, significantly inhibit the function of EBNA1 at the cell level, significantly down-regulate the copy number of the Epstein-Barr virus (EBV) genome of PBMC of a nasopharyngeal carcinoma patient in vitro, have good biological safety in mice, provide a new treatment strategy for patients with EB virus positive tumors, and have far-reaching clinical significance and popularization.

The application discloses a spinal muscular atrophy quality control product and a preparation method and application thereof. The application aims at the deficiency that the existing method of using Epstein-Barr virus to immortalize lymphocytes cannot efficiently transform spinal muscular atrophy lymphocytes into immortalized cells, and provides a transformation culture medium and a method for constructing immortalized spinal muscular atrophy lymphocytes by using the culture medium. By using the method, the immortalized spinal muscular atrophy lymphocyte strain can be constructed within 30 days, and the corresponding immortalized cell line can be obtained by subculturing the immortalized spinal muscular atrophy lymphocyte strain. When the immortalized spinal muscular atrophy lymphocytes are constructed by using the method, the required time is short, the success rate is high, the genetic background of the obtained immortalized cells is stable, the interoperability with clinical samples is high, the compatibility is good, the immortalized cells can be stably preserved, and the immortalized cells can be used as positive quality control products in gene detection of spinal muscular atrophy, so that the accuracy of detection can be ensured.

The invention belongs to the technical field of medical biology, and particularly relates to an EBV (Epstein-Barr Virus) neutralizing antibody-specifically-immune plasma high-throughput screening method and application thereof. EB virus envelope glycoprotein gp350 is selected as a screening target antigen, EBV specific plasma containing a high-titer EBV neutralizing antibody is rapidly screened in a high-throughput mode and used for preparing EBV specific human immune globulin, the titer of the EBV neutralizing antibody is obviously higher than that of listed intravenous gamma-C products, and the content of the EBV neutralizing antibody is about 4-8 times that of the EBV neutralizing antibody with the same concentration. The method provided by the invention can realize large-scale collection of EBV specific plasma through rapid high-throughput screening, reduces the workload of plasma screening, is suitable for large-scale production of EBV specific human immune globulin, and has a good application prospect.

The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.

The present invention relates to the field of immunotherapy, in particular to diseases associated with Epstein-Barr virus (EBV, also known as human gamma herpesvirus 4), such as cancer or post-transplant lymphoproliferative disease, in particular to adoptive T cell therapy or T cell receptor (TCR) gene therapy. The present invention provides a combination of nucleic acids encoding at least two TCR constructs or corresponding proteins or host cells, wherein each TCR construct is capable of specifically binding to its respective epitope in the context of a respective MHC I, and wherein the epitopes are derived from different antigens expressed by the same infectious agent or cancer, such as EBV antigens. The present invention further provides specific nucleic acids encoding a TCR alpha chain construct (TRA) and / or a TCR beta chain construct (TRB) of a TCR construct specific for an epitope complexed with human MHC I, wherein the epitope is an epitope of an Epstein-Barr virus protein, the TCR construct being specific for an epitope from LMP2A, LMP1 or EBNA3C. Proteins encoded by said nucleic acids, corresponding host cells, as well as pharmaceutical compositions and kits are also an object of the present invention.

The disclosure provides live attenuated measles vectors encoding in their genome one or more heterologous genes encoding Epstein-Barr Virus (EBV) proteins, e.g., gp350, gH, gL, and gp42, and variants thereof, as well as nucleic acid constructs encoding such measles vectors. The disclosure also relates to immunogenic compositions comprising live attenuated measles vectors encoding EBV proteins, immunogenic compositions comprising such measles vectors, and use of such measles vectors and immunogenic compositions to induce an immune response to EBV in subjects.

The present disclosure relates to nucleic acid molecules (e.g., self-replicating RNAs (srRNAs) expressing one or more antigenic determinants derived from Epstein-Barr virus (EBV)), recombinant cells containing the nucleic acid molecules and pharmaceutical compositions, and uses of such srRNA molecules, recombinant cells and compositions for eliciting pharmacodynamic effects in a subject. Methods for preventing and / or treating a variety of health conditions associated with EBV infection are also provided.

The invention provides a probe and a kit for detecting EB (Epstein-Barr) virus and application of the probe and the kit. The probes comprise a probe specifically combined with an EBER1 gene and a probe specifically combined with an EBER2 gene; the nucleotide sequence of the probe is shown as any one of SEQ ID NO: 1 to SEQ ID NO: 18. On the basis of the probe, multi-Dig labeling and locked nucleic acid modification are carried out, so that the developing intensity, the probe hybridization efficiency and the stability are improved. On the basis, the probes are combined for use, after combined use, the developing background is further reduced, the specificity is enhanced, and the detection effect is further improved.

This invention relates to providing automated systems and computer-implemented methods for detecting diseases such as nasopharyngeal carcinoma (NPC) based on the analysis of immunofluorescence assay (IFA) images using fuzzy inference (FI) systems or deep learning fuzzy inference (DeLFI) hybrid models. For NPC detection, the systems and methods of this invention will distinguish between Epstein-Barr virus (EBV) early antigen (EA) positive and negative cells and identify cellular patterns indicative of NPC. DeLFI hybrid models require less human evaluation and therefore have the potential to improve the scalability and accuracy of NPC detection.

The invention belongs to the technical field of biological medicine, and relates to a method for inhibiting EB (Epstein-Barr) virus based on a KLRG1 target spot and application. Specifically, the invention provides an application of a KLRG1 inhibitor in prevention and / or treatment of chronic active EB virus infection CAEBV. The invention also provides an application of the KLRG1 detection reagent in auxiliary detection of the CAEBV, and provides a method for screening a potential therapeutic agent for treating the CAEBV.

The invention discloses an EB virus related B cell lymphoma diagnostic kit based on GNAS methylation detection. The invention provides a new marker for diagnosis of EB virus related B cell lymphoma, provides a matched and verified special detection primer, and performs functional reverse verification of 5-aza-2 '-deoxycytidine drug intervention. According to the invention, the potential value of the marker in the aspect of curative effect prediction is defined, and a possible molecular basis is provided for implementing individualized demethylation treatment clinically.

The present invention provides CR2 binding proteins which bind to human CR2, pharmaceutical compositions comprising said CR2 binding proteins and their use in the treatment or prevention of autoimmune and / or inflammatory conditions, infectious diseases and malignancies associated with the Epstein-Barr virus (EBV); and their use as vaccine adjuvants / antigen carriers.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

Early Nasopharyngeal Carcinoma (NPC) detection methods, devices, and kits are provided utilizing novel Epstein-Barr Virus (EBV) EBNA1 antigens to detect serum anti-EBNA1 IgA antibodies with superior correlation to NPC development within four years.

Provided herein are engineered Epstein-Barr virus (EBV) polypeptides, polynucleotides encoding the same, related vectors and vaccine compositions, and related methods of making and using said compositions. The compositions disclosed herein may be useful for vaccination against EBV.

This invention relates to the field of virus detection, specifically to an Epstein-Barr virus (EBV) magnetic particle chemiluminescence immunoassay kit. Through antigen screening, this invention obtains an EBV magnetic particle chemiluminescence immunoassay kit using the natural antigen gp125 protein as the antigen, and optimizes the reagents therein, reducing detection background while increasing antibody stability. Experiments show that the EBV magnetic particle chemiluminescence immunoassay kit of this invention has good stability, high specificity, and high sensitivity. Furthermore, the kit has a simple structure, low time cost for EBV detection, and good stability. It can be combined with a fully automated chemiluminescence analyzer to achieve fully automated high-throughput detection, and has strong clinical application significance.

The invention discloses a centrifugal drive integrated micro-fluidic chip integrating LAMP (loop-mediated isothermal amplification) and CRISPR-Cas12b (clustered regularly interspaced short palindromic repeats) and application of the centrifugal drive integrated micro-fluidic chip, and relates to the technical field of biological chips and virus detection, and the centrifugal drive integrated micro-fluidic chip is provided by integrating nucleic acid extraction / purification, LAMP isothermal amplification and CRISPR-Cas12b specific detection in a single chip. By utilizing the chip, rapid, high-sensitivity, high-specificity and low-pollution detection of the EB virus EBNA1 gene is realized. The method is time-saving and labor-saving, the whole detection process can be completed within 45 minutes, professional operators are not needed, and the method has obvious advantages in detection speed and operability. The scheme has important application value for disease control field screening, rapid shunting of primary medical treatment and early warning and monitoring of tumor-related pathogens.

The invention relates to the technical field of in-vitro diagnosis, and discloses an EB virus and echinococcosis antibody joint detection magnetic immunofluorescence detection micro-fluidic chip which comprises a chip body, the chip body is provided with a sample adding chamber, a liquid separation pool and a detection cavity which are communicated in sequence, and the chip body is further provided with a detergent chamber and a waste liquid pool; the detergent chamber is connected with the detection cavity through a washing valve; a hydrophobic modified layer is arranged on the surface of the inner wall of the washing valve; the opening rotating speed threshold value of the washing valve is higher than the centrifugal rotating speed for realizing plasma separation in the liquid separation pool; and one-step immunoreaction freeze-dried microspheres are preset in the detection cavity. According to the invention, a fluid control switch with a high opening threshold value for a liquid containing a surfactant is constructed by arranging a hydrophobic coating with a specific geometric size at the washing valve, so that the problem that the flow is out of control is solved, and the time sequence accuracy of a multi-step reaction is ensured.

The invention relates to the field of biological pharmacy, in particular to fusion protein, a nano vaccine and application thereof. The fusion protein provided by the invention comprises a fusion protein 1 and / or a fusion protein 2; the fusion protein 1 is prepared from a SpyTag protein and an Rv1498A protein; and the fusion protein 2 comprises a SpyCatcher protein and a gp350 protein. A flavin binding protein Rv1498A in a mycobacterium tuberculosis dodecin-like family is used as a carrier protein, a distal membrane end and a proximal membrane end of an EB virus gp350 extracellular domain are respectively displayed on the surface of the Rv1498A by utilizing a SpyTag-SpyCatcher technology, two immunogenic compounds are obtained, high expression quantity is realized while correct modification and folding of an antigen are ensured, and the EB virus gp350 extracellular domain immunogenic protein Rv1498A can be used for preparing the EB virus gp350 extracellular domain immunogenic protein Rv1498A and the EB virus gp350 extracellular domain Rv1498A immunogenic protein Rv1498A and the EB virus gp350 extracellular domain Rv1498A. And the nano-particle vaccine prepared by the aid of an adjuvant is proved to have better immunogenicity in a mouse body.

In particular, synthetic mRNA is provided that can specifically induce transcription of one or more Epstein-Barr virus (EBV) lysis genes in an EBV infected cell, thereby destroying the cell. Also described herein are methods of synthesizing the mRNA and methods of using the mRNA for the treatment of EBV-related diseases, such as EBV-positive cancer.

Provided herein are proteins that include a Vascular Endothelial Growth Factor A (VEGF-A) protein binding domain; proteins that include an Epstein-Barr Virus BCL-2 homolog (BHRF1) protein binding domain; proteins that include a Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) RBD protein binding domain; proteins that include an Interleukin-7 receptor subunit alpha (IL7R-α) protein binding domain; proteins that include a Programmed death-ligand 1 (PD-L1) protein binding domain; proteins that include a Tropomyosin-receptor kinase A (Trk-A) protein binding domain; and proteins that include an Interleukin-17 (IL-17A) protein binding domain.

Provided herein are engineered Epstein-Barr virus nuclear antigen 1 (EBNA1), coding molecules thereof, vectors and mammalian cell expression systems comprising the same, and polypeptide of interest recombinantly produced by the foregoing. Also provided are methods for the preparation of the engineered EBNA1s, coding molecules thereof, vectors and mammalian cell expression systems and methods for using the same in recombinant expression.

The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer comprising an EZH2 inhibitor and a BTK inhibitor, and it has been confirmed that the therapeutic effect is significantly superior not only in Ebstein-Barr virus (EBV)-associated lymphoma, which has had low therapeutic efficacy until now, but also in other types of cancer.

Described herein are compositions and methods for treating or preventing EBV infection in a subject, and treating or preventing a disease or disorder caused by EBV infection in a subject.